News | 25 May 2023
Mandaviya addresses 76th World Health Assembly
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Ensures efficient testing of FeNO as it is a simple tool for the diagnosis, screening & monitoring of Asthma patients
Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023
The company has reported total income of Rs. 58.42 crores during the period ended March 31, 2023
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
navify Sample Tracking is part of the navify Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.
Anuh Pharma has reported total income of Rs. 158.34 crores during the period ended March 31, 2023
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in their respective categories as on March 2023
The company has reported total income of Rs. 815.11 crores during the period ended March 31, 2023
India’s efforts are aimed at boosting health at the last mile
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
Subscribe To Our Newsletter & Stay Updated
